Group 1 - The core point of the article is that Guangzhou Baiyunshan Zhongyi Pharmaceutical Co., a wholly-owned subsidiary of Baiyunshan, has received a registration certificate for the traditional Chinese medicine An Gong Niu Huang Wan from the Traditional Medicine Management Department of the Vietnamese Ministry of Health [1] - An Gong Niu Huang Wan is classified as a prescription traditional Chinese medicine, with its main functions being to clear heat and detoxify, as well as to calm and open the orifices [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 茲刊載廣州白雲山醫藥集團股份有限公司（「本公司」）在上海證券交易所網站(www.sse.com.cn)刊登的 本公司關於子公司收到越南藥品註冊證書的公告之中文全文，僅供參考。 廣州白雲山醫藥集團股份有限公司 董事會 中國廣州，2025年11月19日 於本公告日，本公司董事會成員包括執行董事李小軍先生、陳傑輝先生、程寧女士、程洪進先生、 唐和平先生與黎洪先生，及獨立非執行董事陳亞進先生、黃民先生、黃龍德先生與孫寶清女士。 证券代码：600332 证券简称：白云山 公告编号：2025－079 广州白云山医药集团股份有限公司 关于子公司收到越南药品注册证书的公告 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出的。 注册持有人：TNHH NEWSEEN COAST 制造商：广州白云山中一药业有限公司 二、药品的其他相关情况 本公司董事会及全体董事保证本公告内容不存在任何虚假记 ...

剂型：丸剂 类别：处方中成药 注册编号：VNCT-00006-25 注册持有人：TNHH NEWSEEN COAST 制造商：广州白云山中一药业有限公司 证券代码：600332 证券简称：白云山 公告编号：2025－079 广州白云山医药集团股份有限公司 关于子公司收到越南药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，广州白云山医药集团股份有限公司（以下简称"本公司"） 全资子公司广州白云山中一药业有限公司（以下简称"中一药业"）收 到越南卫生部传统药品管理局签发的安宫牛黄丸注册证书。现将相关情 况公告如下： 一、药品的基本情况 名称：安宫牛黄丸（Angong Niuhuang Pills） 根据米内网数据显示，2024年安宫牛黄丸在中国城市、县级公立医 院和城市、网上药店的销售额为人民币498,242万元。2024年中一药业安 1 宫牛黄丸的销售收入为人民币15,611.83万元。 截至本公告日，中一药业在安宫牛黄丸药品研发项目上已累计投入 研发费用合计约人民币3,279.81万元（未审计）。 三 ...

Core Viewpoint - The company has received a registration certificate for its product An Gong Niu Huang Wan from the Traditional Medicine Management Department of the Vietnamese Ministry of Health, which will enhance its market presence in Vietnam [1] Group 1: Product Registration - The registration certificate for An Gong Niu Huang Wan allows the product to be sold in Vietnam through TNHH NEWSEEN COAST, a company authorized by 中一药业 [1] - An Gong Niu Huang Wan is indicated for clearing heat and detoxifying, as well as calming and opening the orifices [1] Group 2: Market Expansion - The registration is expected to help 中一药业 expand its business operations in the Vietnamese market, thereby improving the competitiveness of its products [1] - The impact of this registration on the company's current performance is not significant [1]

Core Viewpoint - Baiyunshan (600332.SH) announced that its wholly-owned subsidiary, Zhongyi Pharmaceutical, has received a registration certificate for the traditional medicine An Gong Niu Huang Wan from the Vietnam Ministry of Health, which will be sold in Vietnam through an authorized local company [1] Group 1 - The registration certificate allows Zhongyi Pharmaceutical to expand its business in the Vietnamese market [1] - The impact on the company's current performance is not significant [1] - Sales of pharmaceutical products are subject to market environment changes, indicating potential uncertainties [1]

Core Viewpoint - The company has received a registration certificate for its product, An Gong Niu Huang Wan, from the Traditional Medicine Management Bureau of the Vietnamese Ministry of Health, indicating a significant step in expanding its market presence in Vietnam [1] Group 1: Product Registration - The full subsidiary, Guangzhou Baiyunshan Zhongyi Pharmaceutical Co., Ltd., submitted the drug registration application for An Gong Niu Huang Wan on June 20, 2024 [1] - The product is indicated for clearing heat and detoxifying, as well as calming and opening the orifices [1] Group 2: Financial Performance - The projected sales revenue for An Gong Niu Huang Wan in 2024 is estimated at RMB 156 million [1] - The company has invested approximately RMB 32.7981 million in research and development for this product (unaudited) [1]

Core Viewpoint - Alliance Healthcare Asia Pacific Limited has agreed to transfer its entire 11.04% stake in Nanjing Pharmaceutical to Guangzhou Guangyao Phase II Fund for a total consideration of approximately RMB 748.81 million at a price of RMB 5.18 per share [2][8] Group 1: Share Transfer Details - The share transfer involves 144,557,431 shares, which represents 11.04% of the total share capital of Nanjing Pharmaceutical [2][8] - Following the completion of the transfer, Alliance Healthcare will no longer hold any shares in the company, while Guangzhou Guangyao Phase II Fund will hold the entire 11.04% stake [2][8] Group 2: Strategic Investment Agreement - On September 26, 2025, Nanjing Pharmaceutical's board approved a strategic investment agreement with Guangzhou Baiyunshan Pharmaceutical Group and Guangzhou Guangyao Phase II Fund [6][7] - The agreement aims to establish a long-term strategic partnership based on principles of mutual benefit, resource sharing, and innovation [7] Group 3: Lock-up Commitment - Guangzhou Guangyao Phase II Fund has committed not to transfer the acquired shares for 18 months following the registration of the share transfer, with certain exceptions [3][8] - This commitment includes any shares derived from stock dividends or capital increases during the lock-up period [3][8] Group 4: Regulatory Compliance - The company has disclosed the necessary reports and announcements regarding the share transfer and strategic investment agreement in accordance with regulatory requirements [3][9] - The revised simplified equity change report has been prepared to reflect the updated lock-up commitment [3][9]

1 本次交易尚需上海证券交易所进行合规性确认后方能办理股份过户 等手续，最终能否实施并完成交易尚存在不确定性。本公司将持续关注本 次交易进展，并严格按照有关法律、法规要求及时履行信息披露义务。敬 请广大投资者理性投资，注意投资风险。 证券代码：600332 证券简称：白云山 公告编号：2025－078 广州白云山医药集团股份有限公司 关于广州广药二期基金股权投资合伙企业（有限合伙） 收购南京医药股份有限公司 11.04%股权的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对 其内容的真实性、准确性和完整性承担法律责任。 一、本次交易的基本情况 2025 年 9 月 26 日，广州白云山医药集团股份有限公司（"本公司"） 召开第九届董事会第二十九次会议，审议通过了《关于广州广药二期基金 股权投资合伙企业（有限合伙）收购南京医药股份有限公司 11.04%股份 的议案》。本公司附属企业广州广药二期基金股权投资合伙企业（有限合 伙）（"广药二期基金"）拟以自有资金通过协议转让方式收购 Alliance Healthcare Asia Pacific Limited（"AH ...

海外監管公告 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出的。 茲刊載廣州白雲山醫藥集團股份有限公司（「本公司」）在上海證券交易所網站(www.sse.com.cn)刊登的 本公司關於廣州廣藥二期基金股權投資合夥企業（有限合夥）收購南京醫藥股份有限公司11.04%股權 的進展公告之中文全文，僅供參考。 廣州白雲山醫藥集團股份有限公司 董事會 中國廣州，2025年11月17日 於本公告日，本公司董事會成員包括執行董事李小軍先生、陳傑輝先生、程寧女士、程洪進先生、 唐和平先生與黎洪先生，及獨立非執行董事陳亞進先生、黃民先生、黃龍德先生與孫寶清女士。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对 其内容的真实性、准确性和完整性承担法律责任。 一、本次交易的基本情况 2025 年 9 月 26 日，广州白云山医药集团股份有限公司（"本公司"） 召开 ...

Core Viewpoint - Baiyunshan Pharmaceutical Group has shown a mixed performance in financing activities and stockholder dynamics, with a slight increase in revenue and net profit year-on-year, indicating stable growth in its core business segments [1][2][3] Financing Activities - On November 11, Baiyunshan's financing buy-in amounted to 21.89 million yuan, while financing repayment reached 35.18 million yuan, resulting in a net financing outflow of 13.30 million yuan [1] - The total financing and securities balance for Baiyunshan as of November 11 is 859 million yuan, with the financing balance accounting for 2.23% of the circulating market value, which is above the 70th percentile of the past year [1] - In terms of securities lending, Baiyunshan repaid 1,000 shares and sold 11,000 shares on November 11, with the selling amount calculated at 301,100 yuan, and the remaining securities lending balance is 8.10 million shares [1] Company Overview - Baiyunshan Pharmaceutical Group, established on September 1, 1997, and listed on February 6, 2001, operates in various sectors including traditional Chinese medicine, chemical raw materials, and health management [2] - The company's revenue composition shows that the major commercial segment contributes 69.32%, followed by health products at 16.79%, and traditional medicine at 12.53% [2] - For the period from January to September 2025, Baiyunshan reported a revenue of 61.61 billion yuan, reflecting a year-on-year growth of 4.31%, and a net profit attributable to shareholders of 3.31 billion yuan, up by 4.78% [2] Dividend Distribution - Since its A-share listing, Baiyunshan has distributed a total of 10.91 billion yuan in dividends, with 4.36 billion yuan distributed over the past three years [3] Institutional Holdings - As of September 30, 2025, the top ten circulating shareholders include China Securities Finance Corporation, holding 47.28 million shares, while Hong Kong Central Clearing Limited reduced its holdings by 20.44 million shares [3] - Other notable shareholders include Huatai-PB CSI 300 ETF and E Fund CSI 300 Medical ETF, both of which have seen a decrease in their holdings compared to the previous period [3]